What is Transcend?
Transcend, originally known as Somnetics International, Inc., is a medical device company focused on the design, development, and production of respiratory medical devices. The company has established itself as an emerging leader in treating sleep apnea and related respiratory issues through customer-driven innovation. Its flagship CPAP machine, also named Transcend, has garnered significant industry recognition, including the 2011 Medtrade Innovation Award and the 2012 Medtrade Spring Provider's Choice Award. Further validation came with the 2012 Best Practices Award for Product Differentiation in the Sleep Disordered Breathing market from Frost & Sullivan. The company received FDA market clearance for the Transcend 365 CPAP machine in November 2018 and CE Mark in May 2018, indicating a strong product development pipeline and regulatory success.
How much funding has Transcend raised?
Transcend has raised a total of $933K across 2 funding rounds:
Debt
$350K
Debt
$583K
Debt (2020): $350K with participation from PPP
Debt (2021): $583K led by PPP
Key Investors in Transcend
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Transcend?
The recent major strategic investment signifies a pivotal moment for Transcend, likely enabling the company to accelerate its growth initiatives, expand market reach, and further invest in research and development for its innovative respiratory solutions. This enterprise-level funding suggests a focus on scaling operations and solidifying its position as a key player in the sleep apnea and respiratory disorder treatment market. The company is poised to leverage this capital to enhance its product offerings and potentially explore new therapeutic areas within respiratory care.
See full Transcend company page
